Drugs / JR8603
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06783569 | Dec 2024 → May 2026 overdue | colorectal cancer, gastric cancer, gastroesophageal cancer | JiaRay Group | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JR8603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06783569 ↗ |
| Route | Intravenous | “JR8603 will be administered as a short IV infusion” NCT06783569 ↗ |